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The present study examined whether matrix metalloproteinase-3 (MMP-3) participates in the loss of dopaminergic (DA) neurons
in the nigrostriatal pathway in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson’s disease with
blood brain barrier (BBB) damage and infiltration of peripheral immune cells. Tyrosine hydroxylase (TH) immunostaining of brain
sections from MPTP-treated mice showed that MPTP induced significant degeneration of nigrostriatal DA neurons. Moreover,
FITC-labeled albumin detection and immunostaining revealed that MPTP caused damage to the BBB and increased the number of
ED-1- and CD-3-immunopositive cells in the substantia nigra (SN). Genetic ablation of MMP-3 reduced the nigrostriatal DA neuron
loss and improved motor function. This neuroprotective effect afforded by MMP-3 deletion was associated with the suppression of
BBB disruption and a decrease in the number of ED-1- and CD-3-immunopositive cells in the SN. These data suggest that MMP-3
could play a crucial role in neurodegenerative diseases such as PD in which BBB damage and neuroinflammation are implicated.

1. Introduction
Parkinson’s disease (PD) is a common neurodegenerative
disease associated with progressive degeneration of the nigrostriatal dopaminergic (DA) pathway [1]. Although the
etiology of PD and the mechanisms that mediate disease
development remain largely unknown, accumulating clinical
and experimental evidence suggests that PD is associated
with neuroinflammatory processes such as microglial activation, T-leukocyte infiltration, and blood brain barrier
(BBB) dysfunction [2–4]. Microglial and/or macrophage
phagocytotic activity [3] and T-leukocyte infiltration [5] are
upregulated in damaged areas of the midbrain of PD patients
and in the brains of MPTP-treated mice, thus giving rise to

the death of DA neurons. Increased BBB permeability [6]
and blood vessel changes [7] have also been reported in PD
patients and similarly contribute to DA neuronal death in
MPTP-treated animal models of PD [8, 9].
Matrix metalloproteinase-3 (MMP-3) is a zinc-dependent
proteolytic enzyme that is converted to active MMP-3
through autocleavage; the active form remodels the extracellular matrix complex (EMC) in the basal lamina which forms
part of the BBB [10]. Besides degradation of ECM molecules,
MMP-3 can activate pro-MMPs (pro-MMP-1, -3, -7, -8, -9,
and -13) and cleave cell adhesion molecules, chemokines,
and cytokines [11]. The widespread distribution of MMP-3
in the brain suggests that it plays a crucial role in the central
nervous system (CNS). MMP-3 is involved in axonal growth,
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neuronal migration and synaptogenesis in brain development
[12, 13], and in synaptic plasticity in learning and memory
[14]. In contrast to these functions, it has been shown
that MMP-3 released from apoptotic neuronal cells causes
microglia activation and increases inflammatory processes in
vitro [15]. In addition, MMP-3 facilitates BBB disruption and
neutrophil influx in the cerebral cortex of LPS-injected mice
as a consequence of its action on the basal lamina and tight
junction proteins [16].
Increasing evidence suggests that MMP-3 plays an important role in the pathogenesis of neurodegenerative diseases
such as Alzheimer’s disease, vascular dementia, ischemic
stroke, and PD [10]. In particular, several in vitro studies
reported that MMP-3 exerted neurotoxic effects on oxidative
stress- and endoplasmic reticulum stress-triggered DA neuronal death through caspase-3 activation [17, 18]. Moreover,
MMP-3 immunoreactivity was elevated in the SN of 6hydroxydopamine-(6-OHDA-) injected rats [19] and colocalized within Lewy bodies in the postmortem brains of PD
patients [20]. Under the neuropathological conditions of PD,
MMP-3 participates in DA neuronal cell death through the
proteolytic cleavage of 𝛼-synuclein in vivo and in vitro [20]. In
addition, ghrelin and exendin-4 have been shown to attenuate
nigrostriatal DA neuronal loss and microglial activation via
inhibition of MMP-3 expression in the MPTP mouse model
of PD [21, 22]. However, in the context of PD, little is known
about the role of MMP-3 in relation to BBB function and
the infiltration of peripheral immune cells in the nigrostriatal
DA system. In the current study, therefore, we have used
the MPTP mouse model of PD with a view to determining
if MMP-3 exacerbates the degeneration of nigrostriatal DA
neurons as a consequence of its action to disrupt the BBB and
allow the infiltration of T leukocytes into the brain.

2. Materials and Methods
2.1. Animals and Treatment. Eight-to nine-week-old male
C57BL/6J mice (MMP+/+ ; Jackson Laboratory) and
C57BL/6J-inbred mice deficient for matrix metalloproteinase-e (MMP-3−/− ) were used [23]. All experiments
were performed in accordance with the approved animal
protocols and guidelines established by Kyung Hee University
(KHUASP(SE)-10-030). For MPTP intoxication, mice
received four intraperitoneal injections of MPTP (20 mg/kg,
free base; Sigma) dissolved in saline at 2 h intervals by
following the previously reported method [24, 25].
2.2. Tissue Preparation and Immunohistochemistry. Mice
brain tissues were prepared for immunostaining as described
previously [24–26]. Briefly, brain sections were rinsed in PBS
and incubated overnight at room temperature with primary
antibodies. The primary antibodies included those directed
against tyrosine hydroxylase (TH, 1 : 2000 dilution; Pel-Freez
Biologicals, Rogers, AR, USA) for DA neurons, ED-1 (CD68,
1 : 1000 dilution; Serotec, Oxford, UK) for phagocytotic
microglia/macrophage, and CD-3 (1 : 500 dilution; Serotec,
Oxford, UK) for T leukocytes. The following day, sections
were rinsed with PBS and 0.5% bovine serum albumin
(BSA), incubated with the appropriate biotinylated secondary
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antibody, and processed with an Avidin-Biotin Complex Kit
(Vectastain ABC kit; Vector Laboratories, Burlingame, CA,
USA). Bound antiserum was visualized by treatment with
0.05% diaminobenzidine-HCl (DAB) and 0.003% hydrogen
peroxide in 0.1 M PB. The DAB reaction was terminated
by rinsing tissues in 0.1 M PB. Labeled tissue sections were
mounted on gelatin-coated slides and analyzed under a
bright-field microscope (Nikon, Melville, NY, USA).
2.3. Stereological Cell Counts. The unbiased stereological
estimation of the total number of the TH-ip neurons was
made using the optical fractionator method performed on an
Olympus Computer-Assisted Stereological Toolbox (CAST)
system version 2.1.4 (Olympus Denmark A/S, Ballerup, Denmark) in the various animal groups at 7 days postinjection
(MPTP or saline) as previously described [25, 27]. Actual
counting was performed using a 100x oil objective. The total
number of neurons was estimated according to the Optical
Fractionator Equation [28]. More than 300 points over all
sections of each specimen were analyzed.
2.4. Densitometric Analysis. As previously described [25, 27],
the optical density of TH-positive fiber in STR was examined
at 5x magnification using the Image Pro Plus system (Version
4.0, Media Cybernetics, Silver Spring, Maryland, USA) on
a computer attached to a light microscope (Zeiss Axioskop,
Oberkochen, Germany) interfaced with a CCD video camera
(Kodak Mega Plus model 1.4 I, New York, NY, USA). To
determine the density of the TH staining in the STR, a square
frame of 700 × 700 mm was placed in the dorsal part of the
STR. A second square frame of 200 × 200 mm was placed in
the region of the corpus callosum to measure background
values. To control variations in background illumination,
the average of background density readings from the corpus
callosum was subtracted from that of density readings of
the striatum for each section. For each animal, the average
of all sections was calculated separately before data were
statistically processed.
2.5. Rotarod Test. We measured the ability of the animal
to balance itself and remain on an accelerating rotarod
(UgoBasile, Comerio, Italy) using two different experimental
designs (fixed mode and accelerating mode) as previously
described [25, 29]. To acclimate mice on the rotarod apparatus, animals were given a training session (10 rpm for
20 min), 7 consecutive days before MPTP injection. Animals
that stayed on the rod without falling during training were
selected and randomly divided into experimental groups.
Seven days after the last MPTP treatment, animals receiving
various treatment regimes were placed on the rotating rod
and tested at 20 rpm for 20 min as fixed mode. On the next
day, mice were tested at different progressively higher speeds
on the rotarod apparatus that accelerates at a constant rate,
from 4 to 40 rpm in 300 s as accelerating mode. The latency
to fall was automatically recorded by magnetic trip plates.
2.6. FITC-Labeled Albumin Assay. As previously described
[9], FITC-labeled albumin (MW = 69-70 kDa, Sigma, St.
Louis, MO, USA) assay was performed for visualization of
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BBB leakage. Three days after MPTP or saline injections,
mice were intranscardially perfused with Hank’s Balanced
Salt Solution containing heparin (10 U/mL) and then immediately by 5 mL FITC-labeled albumin (5 mg/mL, in 0.1 M
phosphate-buffered saline (PBS) buffer) injected at a rate
of 1.5 mL/minute. Brains were dissected from the skull,
postfixed overnight in buffered 4% paraformaldehyde at 4∘ C.
After fixation, the brains were cut into 30 𝜇m slices using a
sliding microtome. Sections were mounted on gelatin-coated
slides, and the FITC-labeled albumin contained vessels that
were examined by confocal microscopy (Carl Zeiss). To
determine the total area for FITC-labeled albumin leakage,
3 or 4 images of SN region were obtained, thresholded using
Imag J, quantified, and normalized by value of PBS injected
MMP-3+/+ mice.
2.7. Statistical Analysis. All values are expressed as mean ±
SEM. Statistical significance (𝑃 < 0.05 for all analyses) was
assessed by two-way ANOVA using Instat 3.05 (GraphPad
Software, San Diego, CA, USA) followed by Bonferroni post
hoc test.

3. Results
3.1. MMP-3 Deficiency Protects Nigrostriatal DA Neurons from
MPTP Neurotoxicity. Mice in each group (MMP-3+/+ or
MMP-3−/− mice) received four intraperitoneal injections of
MPTP (20 mg/kg) or PBS (control) at 2-hour intervals. Seven
days later, brains were removed, and sections were immunostained for TH to specifically detect DA neurons. Consistent
with our recent reports [24–26], there was a significant loss of
TH-immunopositive (ip) cell bodies in the SNpc (Figure 1(b))
and of TH-ip fibers in the STR (Figure 2(b)) at 7 days in
MPTP-injected MMP-3+/+ mice compared with PBS-treated
MMP-3+/+ control mice (Figures 1(a) and 2(a)). TH-ip cells
in the SNpc and TH-ip fibers in the STR were quantified by
stereological counts and densitometric analyses, respectively.
The results showed that MPTP treatment reduced the number
of TH-ip neurons by 59% (Figure 1(e), 𝑃 < 0.001) and
decreased the optical density (OD) of TH-ip fibers by 64%
(Figure 2(e), 𝑃 < 0.001) compared with PBS-treated MMP3+/+ control mice.
In contrast to the above, the results of TH immunohistochemistry demonstrated that in MMP-3-deficient (MMP3−/− ) mice, the loss of TH-ip cell bodies in the SNpc
(Figure 1(d)) and TH-ip fibers in the STR (Figure 2(d)) was
significantly reduced compared to that seen in MPTP-treated
MMP-3+/+ mice (Figures 1(b) and 2(b)). Stereological counts
and densitometric analyses showed that the number of THip neurons in the SNpc and the OD in the STR was higher
by 30% (Figure 1(e); 𝑃 < 0.05) and 31% (Figure 2(e); 𝑃 <
0.05), respectively, in MMP-3−/− mice compared to MMP3+/+ mice. These data confirm our previous finding showing
that MMP-3 participates in MPTP-induced neurotoxicity,
resulting in the degeneration of nigrostriatal DA neurons in
vivo [23].

3
3.2. MMP-3 Deficiency Improves Motor Behavior in MPTP
Mice. We next used two different paradigms of rotarod
performance to examine if MMP-3 affects MPTP-induced
motor behavior [25, 29]. Animals receiving the different
treatment regimens were evaluated 7 days after the last MPTP
injection by measuring the fall time latency for the fixed
mode (20 rpm for 20 min) and for the accelerating mode
(4–40 rpm for 5 min) one day after carrying out the fixed
mode evaluation. In MMP-3+/+ mice, the MPTP treatment
decreased the sustained rotarod time in the fixed mode to
10.41 ± 0.78 min (representing a 48% decrease; 𝑃 < 0.001;
Figure 3(a)) and to 2.93 ± 0.91 min (representing a 37%
decrease) in the accelerating mode (𝑃 < 0.001; Figure 3(b)),
compared with control (PBS treatment). In contrast, this
behavioral dysfunction in MPTP-treated MMP-3+/+ mice
was partially reduced in MMP-3−/− mice, which exhibited
increased falling latencies of 18.52 ± 0.91 min (𝑃 < 0.05;
Figure 3(a)) in the fixed mode and 4.03 ± 0.41 min (𝑃 < 0.05;
Figure 3(b)) in the accelerating mode, respectively. The falling
latency in both paradigms was not significantly different
between PBS-injected MMP-3−/− mice and their wild-type
littermates.
3.3. MMP-3 Deficiency Prevents MPTP-Induced BBB Damage
In Vivo. Increased BBB permeability has been observed in
the midbrains of PD patients [6, 30]. In this regard, several
in vivo studies have also demonstrated that increased BBB
permeability can play an important role in the induction of
DA neuronal death in the MPTP mouse model of PD [8, 31].
Thus, we next investigated whether MMP-3 affects MPTPinduced BBB disruption by detecting FITC-labeled albumin
in the brain three days after the last MPTP treatment. In
PBS-injected MMP-3+/+ (Figure 4(a)) and MMP-3−/− mice
(Figure 4(c)), FITC-labeled albumin was confined to the
blood vessels of the SN in vivo, indicating that the BBB
was intact. However, in the SN of MPTP-treated MMP-3+/+
mice, the diffusion of FITC-labeled albumin into the brain
from multiple blood vessels was clearly evident (𝑃 < 0.01;
Figures 4(b) and 4(e)). In contrast, the vascular diffusion of
FITC-labeled albumin was not as clear-cut in MPTP-treated
MMP-3−/− mice (𝑃 < 0.05; Figures 4(d) and 4(e)). These
results suggest that MMP-3 could be involved in an MPTPinduced damage to the BBB.
3.4. MMP-3 Deficiency Inhibits Microglial Activation and the
Infiltration of T Cells into the SN In Vivo. Accumulating evidence, including that from our group, suggests that activated
microglia play an important role in DA neuronal cell death
in the MPTP mouse model [3, 32]. Accordingly, we next
examined if the resistance to MPTP neurotoxicity exhibited
by MMP-3-deficient mice could result from the inhibition
of microglial activation in the SN. Three days after the last
MPTP injection, sections of brain tissue from mice were
immunostained with ED-1 antibody, a marker for activated
microglia. In contrast to the SN of control mice (MMP-3+/+
mice) treated with PBS (Figure 5(a)), where relatively few ED1-ip microglia were observed, the SN of MPTP-treated MMP3+/+ mice contained numerous ED-1-ip cells. The majority
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Figure 1: MPTP-induced neurotoxicity is attenuated in the SNpc of MMP-3−/− mouse brain. (a) Animals (MMP-3+/+ or MMP-3−/− mice)
receiving PBS as a control (a and c) and MPTP (b and d) were sacrificed 7 days after the last MPTP injection. Insets, higher magnifications of
(a–c). The brain tissues were cut into 30 𝜇m thick coronal sections using a sliding microtome and immunostained with an antibody against
the DA neuronal marker TH. Scale bar, 300 𝜇m. (e) Bars represent the number of TH-ip neurons in the SN after indicated treatment in
the absence (MMP-3−/− ) or presence (MMP-3+/+ ) of MMP-3. Five to six animals were used for each experimental group. Two-way ANOVA
with Bonferroni post hoc test (𝐹(1, 15) = 17.57, 𝑃 < 0.001), ∗∗∗ 𝑃 < 0.001, significantly different from PBS-injected MMP-3+/+ mice; # 𝑃 <
0.05, significantly different from MPTP-injected MMP-3+/+ mice. SNpc, substantia nigra pars compacta; VTA, ventral tegmental area; SNr,
substantia nigra reticulata.

of ED-1-ip microglia in the MPTP-treated SN of MMP-3+/+
mice displayed an activated morphology, including larger cell
bodies with short and thick processes or no processes at all
(Figure 5(b)). In contrast, the number of ED-1-ip-activated
microglia was clearly decreased in the SN of MPTP-treated
MMP-3−/− mice (Figures 5(c) and 5(g)).

Recent studies have shown that the migration of peripheral T lymphocytes within the CNS is associated with DA
neuronal death in the SN of PD patients and of MPTP-treated
mice [5, 33]. Accordingly, we examined whether a deficiency
of MMP-3 inhibits the infiltration of T lymphocytes. As
described previously [32], the MPTP-induced infiltration of
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Figure 2: MPTP-induced neurotoxicity is attenuated in the striatum of MMP-3−/− mouse brain. Striatal tissues obtained from the same
animals as used in Figure 1 were immunostained with TH antibody for DA fibers. Animals were treated with PBS as a control (a and c) and
MPTP (b and d). (e) Bars represent optical density of TH-ip fibers in the striatum. Scale bar, 250 𝜇m. Five to six animals were used for each
experimental group. Two-way ANOVA with Bonferroni post hoc test (𝐹(1, 15) = 22.22, 𝑃 < 0.001), ∗∗∗ 𝑃 < 0.001, significantly different
from PBS-injected MMP-3+/+ mice; # 𝑃 < 0.05, significantly different from MPTP-injected MMP-3+/+ mice.

T cells was visualized by CD-3 immunostaining of sections
adjacent to those used for ED-1 immunostaining. Compared
with the SN of PBS-treated MMP-3+/+ mice (Figure 5(d)), a
14-fold increase in the number of CD-3-ip cells in the SN of
MPTP-treated MMP-3+/+ mice was seen three days after the
last MPTP injection (𝑃 < 0.001; Figures 5(e) and 5(g)). By

comparison, the number of CD-3-ip cells in the SN of MMP3−/− mice was 79% lower than that in the MMP-3+/+ mice
(𝑃 < 0.05; Figures 5(f) and 5(g)). Stereological cell counting
showed that the numbers of ED-1 and CD-3-ip cells in the SN
were similar between PBS-injected MMP-3−/− mice and their
wild-type littermates (Figure 5(g)).
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Figure 3: Effects of MMP-3 on motor performance in MPTP-treated mice. (a) After 7 days from MPTP injection, mice were subjected
to rotating rod (20 rpm) for 20 min, and falling time was recorded. (b) Next day, mice were placed on an accelerating rotating rod, and the
maximum time before the mouse fell from the rod was recorded. Five to six animals were used for each experimental group. Two way ANOVA
with Bonferroni post hoc test, fixed mode; (𝐹(1, 15) = 45.67, 𝑃 < 0.001), accelerating mode; (𝐹(1, 15) = 9.73, 𝑃 < 0.01), ∗∗∗ 𝑃 < 0.001
and ∗∗ 𝑃 < 0.01, significantly different from PBS-injected MMP-3+/+ mice; # 𝑃 < 0.05, significantly different from MPTP injected MMP-3+/+
mice.

4. Discussion
Accumulating evidence suggests that MMP-3 is associated
with DA neuronal death and neuroinflammation and as
a consequence is involved in the pathogenesis of PD [10,
34]. Several studies have previously shown that MMP-3
plays an important role in caspase signaling under ER
stress [35] or BH-4- [36] induced apoptotic DA neuronal
death and is involved in the induction of reactive oxygen
species (ROS) and proinflammatory cytokine production in
activated microglia [15]. The pharmacological inhibition of
MMP-3 recovers motor deficits and suppresses microglia
activation in MPTP-treated mice [37]. We have shown here,
for the first time, that in addition to degeneration of DA
neurons and microglial activation, MMP-3 participates in the
impairment of BBB integrity and T-leukocyte infiltration into
the SN of MPTP-treated MMP-3+/+ mice.
Neuroinflammation can be produced by many factors,
including activated microglia, BBB disruption, and infiltration of peripheral immune cells into the brain and as
such plays a critical role in the CNS immune system [38].
Intrinsic immune mechanisms perform neuroprotective and
supportive functions in the normal CNS; however, under
neuropathological conditions, neuroinflammation may be
triggered by transient initiation factors such as neuronal
damage, thereby contributing to irreversible DA neuronal
death in the SN and locomotor deficits [39].
The pathogenesis of PD has been linked increasingly
to neuroinflammation and BBB impairment [40–42]. Neuroinflammation was found to exert harmful effects on BBB
integrity [43], and BBB leakage has been demonstrated in PD
patients [6, 30] and in MPTP- or 6-OHDA-treated animal
models of PD [9, 44]. Because the BBB helps regulate and
protect the microenvironment of the brain and its disruption

results in the loss of DA neurons [45], it has been hypothesized that BBB dysfunction may account for, at least in part
the degeneration of DA neurons in PD [46, 47].
The BBB, which is comprised of neurovascular units such
as endothelial cells, pericytes, neurons, and astrocyte endfeet, restricts the entry of plasma components, blood cells,
and leukocytes into the brain. When these infiltrate into
the brain parenchyma due to neurodegenerative processes or
neuroinflammation, neurotoxic substances can be produced
that cause neuronal dysfunction and loss [43]. We recently
demonstrated in LPS-treated rats and MPTP-treated mice
that compromising the integrity of the BBB contributes to
the degeneration of nigrostriatal DA neurons in the SN [32].
The present data show that MPTP increases the infiltration
of FITC-labeled albumin from blood vessels into the SN and
that genetic deletion of the MMP-3 (i.e., MMP-3−/− mice)
likely attenuates the MPTP-induced damage to the BBB and
subsequent impact on the SN.
Glial cell activation is one of the major contributors to
neuroinflammation and is implicated in the pathogenesis and
progression of PD [32, 38]. In particular, activated microglia
can release harmful substances such as proinflammatory
cytokines, ROS, and reactive nitrogen species which subsequently cause neuronal loss and dysfunction in a range of
neurodegenerative diseases [3]. Several studies have demonstrated that reactive microglia expressing proinflammatory
mediators are present in the midbrains of PD patients [48–
50], while increasing evidence, including our own [24–
26], has shown that activated microglia contribute to DA
neuronal cell death through NADPH- [50] and MPO- [48]
mediated oxidative stress and production of proinflammatory
molecules (iNOS, TNF-𝛼, and IL-1𝛽) [51] in the MPTP mouse
model of PD. Recently, we reported that the number of CD11b- and Iba-1-ip-activated microglia was correlated with ED1-ip microglia/macrophage phagocytotic activity in the SN
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Figure 4: MPTP-induced BBB breakage is prevented in MMP-3−/− mice. At 3 days after MPTP injection in the absence (MMP-3−/− ; (c and d))
or presence (MMP-3+/+ ; (a and b)) of MMP-3, FITC-linked albumin was administered to detect for brain vascular permeability. (e) Bars
represent the FITC-labeled albumin-positive area in the SNpc, respectively. Four or five animals were used for each experimental group.
Whole values are normalized by PBS-injected MMP-3+/+ mice. Two-way ANOVA with Bonferroni post hoc test (𝐹(1, 15) = 10.19, 𝑃 < 0.001).
∗∗
𝑃 < 0.01, significantly different from PBS-injected MMP-3+/+ mice; # 𝑃 < 0.05, significantly different from MPTP-injected MMP-3+/+ mice.
Arrows indicate FITC-linked albumin leakage, indicating extravasations of FITC-labeled albumin into the brain. Dotted lines indicate the
SNpc, where DA neurons were degenerating after MPTP injection. Scale bar, 400 𝜇m.
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Figure 5: MPTP-induced increases in ED-1 and CD-3-ip cells are suppressed in the SNpc of MMP-3−/− mouse brain. ((a–f)) Sections adjacent
to those used for FITC-linked albumin staining were examined for ED-1 or CD-3 immunostaining. (g) Bars represent the numbers of ED-1
or CD-3-ip cells in the SNpc, respectively. Four or five animals were used for each experimental group. Dotted lines indicate the SNpc. Scale
bar, 100 𝜇m. Two-way ANOVA with Bonferroni post hoc test, ED-1-ip cells; (𝐹(1, 15) = 45.67, 𝑃 < 0.001), CD-3-ip cells; (𝐹(1, 15) = 13.72,
𝑃 < 0.01), ∗∗∗ 𝑃 < 0.001, significantly different from PBS-injected MMP-3+/+ mice; # 𝑃 < 0.05, significantly different from MPTP-injected
MMP-3+/+ mice.

of MPTP-treated mice [26]. With respect to that finding,
the present study shows that MPTP significantly upregulated
the expression of ED-1-ip microglia in the SN. In contrast,
the increase in number of ED-1-ip cells was dramatically
attenuated in the MPTP-treated SN of MMP-3 knockout
(MMP-3−/− ) mice. These data support the hypothesis that

MMP-3 has the capacity to induce microglial activation,
resulting in the degeneration of DA neurons.
In addition to microglial activation, the infiltration of T
leukocytes may be involved in nigrostriatal DA neuronal
death. Several lines of evidence highlight the presence of
infiltrating T cells (CD-4- or CD-8-ip cells) in the SN of PD
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patients [5] and MPTP-treated mice [5, 33]. Brochard and
colleagues also showed the CD-4- but not CD-8-mediated
degeneration of DA neurons in the SN of MPTP-treated mice
[5]. Depboylu and colleagues recently showed that infiltrating
CD-3-ip T lymphocytes, representing both CD-4-ip and CD8-ip cells, are implicated in the regulation of the adaptive
immune system through crosstalk with microglia and/or
macrophages in the SN in the MPTP mouse model of PD
[33]. Moreover, CD-4-ip T cells mediated (via the Fas/Fas
ligand pathway) the detrimental effects on DA neurons in the
SN of MPTP-treated mice [5]. In this way, the data in this
report show that MPTP increases the number of infiltrating
CD-3-ip T cells in the SN of MMP-3+/+ control mice; this
number was significantly reduced in the SN of MPTP-treated
MMP-3−/− mice, eventually leading to the improved survival
of DA neurons. These data suggest that MMP-3-induced Tcell infiltration contributes to MMP-3’s neurotoxic effect on
DA neurons in the SN.
The predominant behavioral change in the MPTP-treated
mice was the reduced latency to fall from the rotarod
apparatus, thereby reflecting diminished coordination and
balance [24–26]. The two different designs of rotarod performance (fixed mode and accelerating mode) indicate that
nigrostriatal DA neuron loss is well correlated with motor
dysfunction on this apparatus. Consistent with our recent
data [24, 26], MPTP reduced the latency to fall from the
rotarod apparatus in MMP-3+/+ control mice. This behavioral
dysfunction was partially improved in MPTP-treated MMP3−/− mice. These behavioral effects of MMP-3 deletion on the
lesioned nigrostriatal DA system, together with the knowledge that the genetic ablation of MMP-3 prevents microglial
activation, infiltration of T leukocyte, and BBB disruption,
suggest that MMP-3 could be a useful therapeutic target for
treating PD and other neurodegenerative disorders involving
neuroinflammation and compromised BBB integrity.

5. Conclusion
The present study shows that matrix metalloproteinase3 (MMP-3) participates in degeneration of nigrostriatal
dopaminergic neurons in the MPTP model of Parkinson’s
disease by neuroinflammation-mediated BBB disruption and
infiltration of T leukocytes. To our knowledge, this is the first
study to demonstrate that neurotoxic effects of MMP-3 in the
MPTP-treated SN are associated with the ability of MMP-3 to
increase BBB damages, microglia/macrophage phagocytosis,
and infiltration of T leukocytes, suggesting that MMP-3
can be novel therapeutic target for PD and other disorders
associated with BBB integrity and neuroinflammation.
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